New hope for Tough-to-Treat blood cancer
NCT ID NCT07372352
Summary
This study is testing a new combination of three drugs for adults with an aggressive type of blood cancer called peripheral T-cell lymphoma (PTCL) that has returned or not responded to prior treatment. About 26 patients will receive the drug combination for up to 6 cycles, followed by up to 2 years of maintenance therapy with one of the drugs if they respond. The main goal is to see how many patients' tumors shrink and to monitor the safety of this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELLS LYMPHOMA (PTCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.